Calcimimetic agents and secondary hyperparathyroidism: Rationale for use and results from clinical trials

Pediatric Nephrology

Volumn 18, Issue 12, 2003, Pages 1206-1210

  Goodman, William G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Calcimimetic agents; Chronic renal failure; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; R 568; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ALLOSTERISM; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR CALCIUM; GROWTH RETARDATION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; SOFT TISSUE CALCIFICATION;

ANILINE COMPOUNDS; CHILD; CLINICAL TRIALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; NAPHTHALENES; PARATHYROID HORMONE; RECEPTORS, CALCIUM-SENSING;

EID: 0346270563     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1290-2     Document Type: Article

References (28)

1. Slatopolsky E, Delmez JA (1994) Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229-236
2. Parfitt AM (1997) The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52:3-9
3. Mehls O, Wuhl E, Haffner D, Schaefer F, Tonshoff B (1996) Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Nephrol Dial Transplant 11:1747-1750
4. Wuhl E, Haffner D, Nissel R, Schaefer F, Mehls O, and German Study Group for Growth Hormone Treatment in Chronic Renal Failure (1996) Short dialyzed children respond less to growth hormone than patients prior to dialysis. Pediatr Nephrol 10:294-298
5. 3 in childhood renal osteodystrophy. N Engl J Med 298:238-242
6. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during treatment with intermittent calcitriol and dialysis in children with chronic renal failure. Kidney Int 53:205-211
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483
8. Dawson-Hughes B (1991) Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr 54:274S-280S
9. Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239-297
10. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J (2000) Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50-58
11. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983
12. Nemeth EF (1996) Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles in bone biology, 1st edn. Academic Press, San Diego, pp 1019-1035
13. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045
14. Goodman WG (2001) Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187-1201
15. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617
16. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942
17. Brown EM (1993) Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 2:541-551
18. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296-1301
19. Brown EM, Broadus AE, Brennan MF, Gardner DG, Marx SJ, Spiegel AM, Downs RW Jr, Attie M, Aurbach GD (1979) Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 48:604-610
20. Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV, Salusky IB (1993) Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76:1489-1494
21. Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223-227
22. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445
23. Yamaguchi T, Chattopadhyay N, Kifor O, Ye C, Vassilev PM, Sanders JL, Brown EM (2001) Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line. Am J Physiol Cell Physiol 280:C382-C393
24. Yamaguchi T, Kifor O, Chattopadhyay N, Brown EM (1998) Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2. Biochem Biophys Res Commun 243:753-757
25. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024
26. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus product levels in hemodialysis patients with secondary hyperparathyroidism. Kidney Int 63:248-254
27. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583
28. Drüeke T, Cunningham J, Goodman WG, Horl WH, Braun J, Chen M-G, McCary LC, Steinhauslin-Jeanrenaud F, Turner SA, Ritz E (2001) Short-term treatment of secondary hyperparathyroidism with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764